Ceftriaxone reverses ketamine-induced lasting EEG and astrocyte alterations in juvenile mice. (1st November 2015)

• Record Type: Journal Article
• Authors: Dodman, K.; Featherstone, R.E.; Bang, J.; Liang, Y.; Siegel, S.J.
• Is Part Of: Drug and alcohol dependence. Volume 156(2015)
• Page Start: 14
• Page End: 20
• Publication Date: 2015-11-01
• Subjects: Ketamine -- Mouse -- EEG -- Glia -- EAAT2; Drug abuse -- Periodicals; Alcoholism -- Periodicals; 616.86
• DOI: 10.1016/j.drugalcdep.2015.07.1198
• Languages: English
• ISSNs: 0376-8716

Abstract

Abstract: Background: Ketamine, an N-methyl-d -aspartate receptor antagonist, is used as a pediatric anesthetic because of its favorable safety profile. It is also being investigated as an antidepressant. Unfortunately, ketamine causes adverse reactions including hallucinations and is associated with a high prevalence of abuse among adolescents. Although chronic ketamine use has been shown to produce cognitive impairments even years following cessation, little is known about its long-term consequences on adolescents. The beta-lactam ceftriaxone has been shown to attenuate alcohol withdrawal, and alleviate early brain injury and memory impairments following subarachnoid hemorrhage. However, its ability to reverse the effects of adolescent ketamine exposure is not known. Previous data indicate that ketamine causes a reduction in the number of Excitatory Amino Acid Transporter Type 2 (EAAT2)-containing astrocytes. Additionally, the beta lactam antibiotic ceftriaxone increased expression of EAAT2. As EAAT2 is a principal mechanism of glutamate clearance from the synapse, the current study tests the hypothesis that ceftriaxone may reverse functional consequences of ketamine exposure. Methods: We examined the effects of chronic ketamine in juvenile mice as well as reversal by ceftriaxone using electroencephalography (EEG). Subsequently, we assessed the effects of these treatments on markers of astrocyte proliferation, using Glial Fibrillary Acidic Protein (GFAP), and function, as evidenced by EAAT2. Results: Juvenile mice exposed to chronic ketamine showed lasting alterations in EEG measurements as well as markers of astrocyte number and function. These alterations were reversed by ceftriaxone. Conclusions: Data suggest that ceftriaxone may be able to ameliorate ketamine-induced long-term disturbances in adolescent brains.